Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- (-) Biopharmaceutical Innovation
- Clinical Pathways
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- (-) Health Spend Management
- (-) High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- IRA Implementation
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- (-) Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- (-) Value-Based Insurance Design
- (-) Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Audience
Display Only
Showing 39 Results
Barriers and Solutions to the Inclusion of Broader Benefits in Biopharmaceutical Value Assessments
This study evaluated how institutional barriers prevent the inclusion of broader individual and societal benefits associated with new health care innovations from being considered when assessing the…
Current Landscape: Value Assessment Frameworks
This report analyzed seven existing U.S. value assessment frameworks, comparing and contrasting the strengths and limitations associated with each framework.
As Value Assessments Evolve, Are They Ready for Prime Time?
This peer-reviewed study examined the evolution of the value assessment landscape in the United States.
Uptake and Federal Budgetary Impact of Allowing Health Savings Account-eligible High Deductible Health Plans to Cover Chronic Disease Drugs and Services Pre-deductible
This report examines the net federal budgetary impact allowing Health Savings Account-eligible HDHPs to expand pre-deductible coverage to include chronic disease services.
National Pharmaceutical Council 2018 Annual Report
2018 marked NPC’s 65th anniversary as a leader in health research and policy.
What's Been the Bang for the Buck? Cost-Effectiveness of Health Care Spending Across Selected Conditions in the US
This study was designed to assess whether increased medical intervention spending on prevalent chronic conditions has been a good investment over time.
Financial Impact of HSA-HDHP Reform to Improve Access to Chronic Disease Management Medications
According to an issue brief from VBID Health, providing pre-deductible coverage for medicines used to treat common chronic conditions could lower out-of-pocket costs and increase medication adherence…
Regulatory Barriers Impair Alignment of Biopharmaceutical Price and Value
This white paper highlights the challenges biopharmaceutical manufacturers and payers face when developing value-based contracts.
Value Assessment Frameworks: Are They Up To The Challenge?
In this article published on the Health Affairs Blog, NPC researchers Dr. Robert Dubois and Kimberly Westrich ask: Are value assessment frameworks ready to compare the health and economic impacts of…
Concerns Around Budget Impact Thresholds: Not All Drugs Are The Same
A study published in Value in Health explores the potential impact of using budget thresholds as budget caps (e.g., cannot spend more than a set dollar amount) for individual drugs.
Comparison of Value Framework Assessments for Multiple Myeloma
In this NPC-funded study conducted by the Lewin Group, four existing value assessment frameworks were compared head to head to understand how each framework would approach the same condition,…
Assessing Value: Promise and Pitfalls Conference Summary Report
At NPC's conference, Assessing Value: Promise and Pitfalls, top experts in their fields united to discuss value assessment as it impacts payers, patients, providers and pharmaceutical innovators.
A Dynamic Approach to Consumer Cost-Sharing for Prescription Drugs
The level of consumer cost-sharing for higher cost medication should be aligned with the clinical value – not solely the price – when lower cost alternatives do not produce the desired patient…
Guiding Practices for Patient-Centered Value Assessment
In 2016, NP developed Guiding Practices for Patient-Centered Value Assessment that included 28 specific elements, which are broken out into six key aspects of value assessments: the assessment…
Improving the Efficiency and Quality of the Value Assessment Process for Companion Diagnostic Tests: The Companion Test Assessment Tool
This peer-reviewed study examined some of the barriers to incorporating a Companion Diagnostic Test (CDT) into drug treatment decisions and outlined a framework to assist managed care…
Supporting Consumer Access to Specialty Medications Through Value-Based Insurance Design
Value-based insurance design (V-BID) is a key tactic payers and purchasers can use to promote access to high-value specialty medications.
Three Perspectives on the Impact of Comparative Effectiveness Research on Decision Making
In a special supplement to the May 2012 Journal of Managed Care Pharmacy, National Pharmaceutical Council Chief Science Officer Robert W. Dubois, MD, PhD, takes a closer look at comparative…
Health Plan Capabilities to Support Value Based Benefit Design
This guide around health plan capabilities to support Value Based Benefit Design is meant to assist employers in understanding how to more effectively work with their health plans to implement…